Research Analysts’ Weekly Ratings Updates for Progyny (PGNY)

Several brokerages have updated their recommendations and price targets on shares of Progyny (NASDAQ: PGNY) in the last few weeks:

• 7/28/2026 – Progyny had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $34.00 price target on the stock, up from $27.00.
• 7/25/2026 – Progyny was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/24/2026 – Progyny had its price target raised by BTIG Research from $30.00 to $40.00. They now have a “buy” rating on the stock.
• 7/22/2026 – Progyny was given a new $38.00 price target by Leerink Partners.
• 7/21/2026 – Progyny had its price target raised by Canaccord Genuity Group Inc. from $30.00 to $36.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Progyny had its price target raised by KeyCorp from $30.00 to $35.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Progyny was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/27/2026 – Progyny was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/26/2026 – Progyny was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 6/22/2026 – Progyny had its price target raised by Truist Financial Corporation from $30.00 to $33.00. They now have a “buy” rating on the stock.
• 6/5/2026 – Progyny was downgraded by Zacks Research from “strong-buy” to “hold”.
• 6/2/2026 – Progyny had its price target raised by Bank of America Corporation from $29.00 to $31.00. They now have a “buy” rating on the stock.

Insider Activity at Progyny

In other Progyny news, CFO Mark S. Livingston sold 2,517 shares of Progyny stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $25.50, for a total value of $64,183.50. Following the transaction, the chief financial officer owned 74,688 shares in the company, valued at $1,904,544. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the transaction, the insider owned 59,117 shares of the company’s stock, valued at $1,512,212.86. This represents a 2.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 36,916 shares of company stock valued at $939,875 over the last 90 days. Company insiders own 9.90% of the company’s stock.

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.